Court
– The District Court of the Hague (Netherlands) rejected a patent revocation suit brought by Mylan’s Dutch unit. – – The District Court of...
Hi, what are you looking for?
– The District Court of the Hague (Netherlands) rejected a patent revocation suit brought by Mylan’s Dutch unit. – – The District Court of...
– Credit Suisse sees Copaxone sales falling from $4 billion annually to $400, 000 in 2019 and predicts annual sales of over $1 billion...
– Teva Pharmaceutical Industries Ltd. has chalked up a victory in the UK against Mylan Inc., stating that their Copaxone patents are valid through...
– Products developed by the Weizmann Institute have $20 billion in annual sales. – – / By Gali Weinreb / The campus of the...
– The decision maintains exclusivity for Copaxone until May 24, 2014. – Copaxone/ source : dynamik3d.ca – On Friday, the US Court of Appeals for...
– The Southern District of New York dismissed Teva’s lawsuit against Mylan for the infringement of patents on its MS treatment. – Teva Pharmaceutical...